News by topic

Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

New and experimental HIV treatments news

Show

From To
New and experimental HIV treatments
South Africa: New safety concerns emerge on latest HIV wonder drug

New safety concerns have emerged about the HIV drug dolutegravir, which the government plans to roll out in April.

Published
18 January 2019
From
Business Day
New and experimental HIV treatments
Dolutegravir monotherapy 'not a valid option' for patients with HIV

Study results showed that dolutegravir monotherapy “is not a valid option” to keep patients with chronic HIV infection virologically suppressed and should not be considered a treatment option, researchers said.

Published
15 January 2019
From
Healio
Side-effects
Do integrase inhibitors raise the risk of obesity?

People who take an integrase inhibitor as part of their HIV treatment appear to gain more weight than others after starting treatment and the trend is more

Published
10 January 2019
By
Keith Alcorn
Low CD4 count
‘Left behind’: Drug companies and researchers have overlooked patients who don’t respond to HIV meds

There are tens of thousands of immunologic non-responders in the U.S., whose low CD4 numbers put them at much higher risk of heart attacks, stroke, cancers, secondary infections such as tuberculosis, and death. And yet, drug companies and researchers aren’t actively pursuing new treatments that would boost their immunity.

Published
08 January 2019
From
STAT
Access to medicines and treatment
Benefits of dolutegravir treatment for all substantially outweigh the risks

Providing an antiretroviral regimen of dolutegravir, tenofovir and lamivudine to all adults living with HIV in sub-Saharan Africa, regardless of viral suppression or plans to have children,

Published
17 December 2018
By
Keith Alcorn
Pharmaceutical industry
Biktarvy's success raises doubts about ViiV's 'new era' of HIV treatment

GlaxoSmithKline subsidiary ViiV Healthcare believes its portfolio of HIV medications will be competitive as treatment for the virus enters an era of two-drug regimens. So far, however, the company's first doublet has performed modestly on the market compared to a key rival's three-drug regimen.

Published
12 December 2018
From
BioPharma Dive
New and experimental HIV treatments
European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine)

Merck, known as MSD outside the United States and Canada, today announced that the European Commission has approved DELSTRIGO™ and PIFELTRO™ for the treatment of HIV-1 infection. DELSTRIGO is a new once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg).

Published
28 November 2018
From
Merch press release
New and experimental HIV treatments
Tivicay Plus Boosted Prezista Shows Promise as Two-Drug HIV Regimen

However, the regimen appears much less potent for those who aren’t virally suppressed.

Published
16 November 2018
From
Poz
New and experimental HIV treatments
Fostemsavir, novel gp120 inhibitor, salvages nearly half of people with no other treatment options left

The recent International Congress on Drug Therapy in HIV Infection (HIV Glasgow) featured trials of several HIV drugs with modes of action different from the usual

Published
07 November 2018
By
Gus Cairns
Long-acting HIV treatment
ViiV’s Long-Acting Injectable HIV Regimen Boasts Good 3-Year Results

The company has released new data from a trial of injectable cabotegravir and Edurant given every four or eight weeks.

Published
05 November 2018
From
Poz
← Prev1...23456...110Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.